ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Personality Disorder (BPD)

by Oryzon Genomics

6 months ago
vafidemstat, ORYZON, Borderline Personality Disorder (BPD)

Oryzon Genomics, S.A. today announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder (BPD). Multiple primary ...

ORYZON to provide corporate progress updates at several events in November

by Oryzon Genomics

6 months ago
BIO-Europe 2023, LSX Investival Showcase 2023, Jefferies London Healthcare Conference 2023, Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...

Oryzon reports financial results and corporate updates for quarter ended September 30, 2023

by Oryzon Genomics

6 months ago
Oryzon Genomics

Research and development (R&D) expenses were $3.8 and $12.2 million for the quarter and nine months ended September 30, 2023, respectively, compared to $4.3 and $11.9 million for the quarter and nine ...

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

7 months ago
borderline personality disorder (BPD), Phase IIb PORTICO, vafidemstat

ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies

by Oryzon Genomics

7 months ago
DICTIONIS Project, MODERN Project

Two collaborative projects with Public Research Centers with a global budget of 2.3 million euros focused on the discovery and validation of new biomarkers and epigenetic targets in the treatment of n...

ORYZON to provide corporate progress updates at several events in October

by Oryzon Genomics

ORYZON to give updates on corporate progress in September

by Oryzon Genomics

Oryzon announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

9 months ago
Borderline Personality Disorder (BPD), vafidemstat

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reports that full patient recruitment ...

ORYZON reports financial results and corporate updates for half-year ending June 30, 2023

by Oryzon Genomics

9 months ago
vafidemstat in CNS, ORYZON

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the hal...

Positive aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

10 months ago
Borderline Personality Disorder (BDP), vafidemstat

Oryzon Genomics today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP).

Positive preclinical data of ORY-4001 for the treatment of Charcot-Marie-Tooth (CMT) disease presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

by Oryzon Genomics

11 months ago
Charcot-Marie-Tooth (CMT), ORY-4001, histone deacetylase 6 (HDAC-6)

Oryzon Genomics, S.A., presented yesterday positive preclinical efficacy data of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor

ORYZON to present positive preclinical efficacy data of ORY-4001 in Charcot-Marie-Tooth (CMT) disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

by Oryzon Genomics

11 months ago
ORY-4001, Charcot-Marie-Tooth (CMT) disease

Oryzon announced today that it will present positive preclinical efficacy data of ORY-4001 in a CMT model at the 2023 Peripheral Nerve Society (PNS) Annual Meeting, which will be held June 17-20 at th...